Navigation Links
Higher drug doses needed to defeat tuberculosis, UT Southwestern researchers report

DALLAS July 30, 2009 The typical dose of a medication considered pivotal in treating tuberculosis effectively is much too low to account for modern-day physiques, UT Southwestern Medical Center researchers said.

The finding, reported online and in the August edition of Antimicrobial Agents and Chemotherapy, is particularly important for those living in societies plagued by obesity, said Dr. Tawanda Gumbo, associate professor of internal medicine at UT Southwestern and the study's lead author.

"What really drives the variability of this particular drug is patient weight and gender, so in our simulations we took that into account," Dr. Gumbo said. "What we found is that we're really using doses for very skinny people 105 to 110 pounds. I haven't met many adults who are at that weight."

About one-third of the world's population is infected with Mycobacterium tuberculosis, the bacterium that causes TB, and as many as 2 million people die from the disease each year. TB, which is the leading cause of death among people infected with HIV/AIDS, kills more people than any other disease caused by a single infectious agent, according to the National Institutes of Health. Treatment usually lasts six to 12 months and includes a combination of antibiotics such as Pyrazinamide, the drug examined in this study.

Because treatment typically includes multiple drugs, introducing new ones to existing regimens has made it harder to identify which, if any, of the drugs are working at the current dosage levels. Researchers also have struggled to identify the needed dosage as well as exactly where in the body these drugs work to combat the bacterium.

The new model developed at UT Southwestern uses cultured cells to gauge the effectiveness and proper dosage of anti-tuberculosis drugs.

"With this model, we can directly test molecules that have the potential to shorten therapy and go straight to coming up with the doses that you would use in patients," Dr. Gumbo said. "What that means is that if you have a molecule that could cure TB in one month in this model, it stands a good chance that it would do the same in patients."

For this study, the researchers gave patients Pyrazinamide an older drug generally used in combination with other drugs daily for one month. The researchers then used the data collected to calculate how much bacteria the drug killed before resistance emerged. They opted to focus on Pyrazinamide because physicians once used it alone to treat the disease, so there are many studies documenting precisely how the drug behaves in patients something that is unclear for some newer drugs.

When the UT Southwestern researchers began testing Pyrazinamide in the lab, they found that the concentration of the drug declined at a rate that matches the rate seen in patients.

"In patients, unlike in test tubes, it's not a constant concentration. A patient given multiple drugs degrades each of them at different rates," he said. "Using this model, we can actually copy this concentration profile of the drugs to human-like exposures."

Dr. Gumbo said his team's finding that the doses traditionally given to tuberculosis patients are much too low suggests that different doses are probably needed in different countries. "Most of the patients we see here in Dallas are not 110 pounds unless they have some other severe disease," he added.

The next step, Dr. Gumbo said, is to continue researching drug combinations in order to devise the optimum treatment regimen for tuberculosis patients.

"We've rationally and scientifically come up with a dose that depends not just on the kinetics or the concentration time profile of patients, but also how the bug itself responds to that particular drug," he said. "So, instead of using the average patient or a mean patient, we can now project how a drug combination will fare in actual patients. With this model, researchers can use these simulations to determine the duration of therapy, which could shorten from years to months."


Contact: Kristen Holland Shear
UT Southwestern Medical Center

Related medicine news :

1. Connectyx Technologies Holdings Group, Inc. to Begin Process to Become Fully Reporting and Up List to a Higher Exchange - As Stated on
2. Beta-Blockers Tied to Higher Cataract Risk
3. Deaths, Injuries Increase With Higher Speed Limits
4. Lower IQ Linked to Higher Risk of Heart Deaths
5. Children of undocumented parents may be at higher developmental risk
6. Mothers of children with autism have higher parental stress, psychological distress
7. Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported
8. Obese Get Higher Doses of Radiation for X-Rays
9. Low Blood Sugar in Hospital Tied to Higher Death Risk for Diabetics
10. Abused Kids Face Higher Cancer Risk
11. Study Finds Skin Cancer Rates Higher Among Athletes
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed ...   ... Jim Bertolina, ... Tom Tefft ... medical device executive Josh Stopek , PhD, who has led R&D and business development ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis ... global supply chains, has published the first annual edition of its Global ... more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that ... ... Risk & Performance Index ...
Breaking Medicine Technology: